EU approval for Octapharma's Nuwiq across all age groups in hemophilia A

7 August 2014
2019_biotech_test_vial_discovery_big

The European Commission has approved independent Swiss biotech firm Octapharma's Nuwiq (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with hemophilia A (congenital factor VIII [FVIII] deficiency).

Nuwiq is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin, the company stated. Nuwiq is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor, both of which are potentially important properties in reducing FVIII inhibitor formation. The development of Nuwiq aimed to address the challenges of inhibitor formation as well as the frequent infusions required for prophylaxis of bleeding.

"Nuwiq represents a potential leap forward in dealing with the greatest clinical challenges in hemophilia A, FVIII inhibitors and the frequent infusions needed for bleeding prophylaxis. In clinical trials, Nuwiq demonstrated outstanding efficacy in preventing and treating bleeding in patients previously on FVIII (PTPs). No inhibitors in clinical trials in PTPs have been seen," says Olaf Walter, senior vice president of international business units.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology